In a patient with restless legs syndrome (RLS) or mast cell activation syndrome (MCAS) who has a normal ferritin level but below the target range of 60–100 ng/mL and is medication‑sensitive, how should iron supplementation be initiated and titrated?

Iron Supplementation in Medication-Sensitive RLS/MCAS Patients with Suboptimal Ferritin

In a medication-sensitive patient with RLS or MCAS who has ferritin below 60-100 ng/mL but technically "normal," start with low-dose oral iron (25 mg elemental iron every other day) and titrate slowly, or proceed directly to IV ferric carboxymaltose if oral iron triggers MCAS symptoms or is not tolerated.

Understanding the Iron Threshold in RLS

The 2025 AASM guidelines establish that RLS requires different iron parameters than the general population 1. The consensus recommendation states that iron supplementation should be instituted when serum ferritin is ≤75 ng/mL OR transferrin saturation <20%, with a target ferritin of 100 ng/mL or higher 1. This is not about treating anemia—it's about correcting brain iron deficiency that drives RLS pathophysiology.

Your patient's "normal" ferritin is actually suboptimal for RLS management. Recent evidence from 2025 demonstrates that IV iron is effective and safe even in patients with ferritin between 100-300 ng/mL 2, challenging the notion that "normal" ferritin means adequate iron status in RLS.

Treatment Algorithm for Medication-Sensitive Patients

Step 1: Verify Iron Parameters

• Measure ferritin AND transferrin saturation (TSAT) in the morning
• Avoid iron-containing supplements/foods for 24 hours before testing 1
• Critical caveat: Ferritin assays vary significantly by manufacturer. A Beckman ferritin of 75 ng/mL equals approximately 121 ng/mL on Roche assays 3. Know which assay your lab uses.
• TSAT ≤35% is a more sensitive predictor of treatment response than ferritin alone 4

Step 2: Choose Iron Formulation Based on Sensitivity Profile

For oral iron (if MCAS/medication sensitivity is mild-moderate):

• Start with 25 mg elemental iron (half of standard 65 mg ferrous sulfate tablet) every other day 1
• Take on empty stomach with vitamin C (enhances absorption)
• Alternate-day dosing reduces GI side effects while maintaining efficacy
• Titrate up to 65 mg daily only if tolerated after 2-4 weeks
• The AASM conditionally recommends ferrous sulfate for adults with appropriate iron status 1

For IV iron (if oral iron not tolerated or MCAS symptoms triggered):

• IV ferric carboxymaltose 1000 mg is the strongest recommendation (strong recommendation, moderate certainty) 1
• This is a single-dose infusion, minimizing repeated medication exposures
• Dilute in 100 mL normal saline, infuse over 15-30 minutes 5
• Pre-medication is typically NOT required unless prior hypersensitivity reactions
• For MCAS patients: Consider pre-treatment with H1/H2 blockers and slow infusion rate

Step 3: Address MCAS-Specific Concerns

Common pitfall: Assuming all reactions are allergic. Most IV iron reactions are infusion-related reactions (IRRs), not true allergies, and respond to slowing infusion rate 5.

For MCAS patients specifically:

• IV ferric carboxymaltose has lower immunogenic potential than older formulations
• Consider pre-medication: H1 blocker (diphenhydramine 25-50 mg) + H2 blocker (famotidine 20 mg) 30 minutes before infusion
• Start infusion at half-rate for first 5 minutes, then increase if tolerated
• Have emergency medications available but recognize true anaphylaxis is rare (<0.1%)

Step 4: Monitor Response

Timeline expectations:

• Oral iron: Improvement may take 3-6 months 6
• IV iron: Symptom improvement typically begins at 4 weeks, with maximal benefit by 12 weeks 7
• Do not recheck iron parameters for 4-8 weeks post-IV iron (circulating iron interferes with assays) 5

Target parameters:

• Ferritin >100 ng/mL (adjust for assay type)
• TSAT >20%
• IRLS score reduction ≥5 points indicates clinically meaningful improvement

Step 5: Maintenance Strategy

If ongoing losses or malabsorption (common in MCAS with GI involvement):

• Recheck CBC and iron parameters every 3-6 months
• Repeat IV iron when ferritin drops below 100 ng/mL
• Oral maintenance (25-65 mg every other day) if tolerated and no malabsorption

Why This Approach Works for Medication-Sensitive Patients

The evidence strongly favors IV iron over oral in your scenario:

1. Single exposure vs. daily medication (reduces cumulative sensitivity risk)
2. Bypasses GI absorption issues common in MCAS
3. More predictable and robust response 2
4. The 2025 guidelines give IV ferric carboxymaltose the highest recommendation strength 1

Oral iron remains an option if the patient strongly prefers it, but use the lowest effective dose with alternate-day dosing to minimize GI symptoms that could trigger MCAS 1.

Critical Caveats

• Transferrin saturation >45% post-treatment warrants monitoring but rarely causes harm. Only 2/58 patients in one study exceeded this threshold, with no hepatic dysfunction 2
• Hypophosphatemia can occur transiently with IV iron but is typically asymptomatic 4
• Address exacerbating factors first: antihistamines (paradoxically worsen RLS), SSRIs, caffeine, alcohol 1
• Pregnancy: Iron therapy is safe but formulation choice matters—consult obstetrics for IV iron 5

The Bottom Line

Your patient's ferritin is suboptimal for RLS regardless of being "normal" by general population standards. Given medication sensitivity, either start with ultra-low-dose oral iron (25 mg every other day) or proceed directly to single-dose IV ferric carboxymaltose 1000 mg with MCAS precautions. The IV route offers superior efficacy, faster response, and paradoxically fewer total medication exposures than months of daily oral iron 1, 2. Monitor at 4-8 weeks and target ferritin >100 ng/mL.